Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-ranging study of BCX9930 in healthy subjects and PNH
NCT04330534Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Mar 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BioCryst Pharmaceuticals, Inc.. Started Mar 2020; status: completed.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04330534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330534.